Objectives: Takayasu arteritis (TAK) is an inflammatory vasculitis that affects the aorta and its primary branches. The pathogenesis of TAK remains elusive, yet identifying key cell types in the aorta of TAK patients is crucial for uncovering cellular heterogeneity and discovering potential therapeutic targets.
Methods: This study utilized single-cell transcriptome analysis on aortic specimens from three TAK patients, with control data sourced from a publicly available database (GSE155468). Additionally, bulk RNA sequencing was performed on peripheral CD4 + and CD8 + T cells from eight TAK patients and eight matched healthy volunteers. All participants were recruited at Anzhen Hospital, Capital Medical University, China, between January 2020 and December 2023.
Results: Single-cell transcriptome analysis identified 11 predominant cell types in aortic tissues, with notable differences in proportions between TAK patients and controls. T cells, B cells, macrophages, smooth muscle cells (SMCs), and fibroblasts exhibited subtype-specific gene expression signatures, with notable changes in interactions between T cells, B cells, and monocyte-macrophages, highlighting their active involvement in the pathogenesis of TAK. Bulk RNA-Seq analysis of peripheral blood T cells from TAK patients showed an upregulation of complement system genes, underscoring the significance of the complement signaling pathway in TAK's immunopathogenesis.
Conclusion: The findings underscore the active involvement of various immune and structural cells in the aortic tissues of TAK patients and reveal the presence of the complement signaling pathway in peripheral blood T cells. These insights are instrumental for identifying novel therapeutic targets and developing robust disease monitoring methods for TAK.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1186/s13075-025-03523-w | DOI Listing |
Arthritis Res Ther
March 2025
Department of Rheumatology and Immunology, Capital Medical University Affiliated Anzhen Hospital, Beijing, China.
Objectives: Takayasu arteritis (TAK) is an inflammatory vasculitis that affects the aorta and its primary branches. The pathogenesis of TAK remains elusive, yet identifying key cell types in the aorta of TAK patients is crucial for uncovering cellular heterogeneity and discovering potential therapeutic targets.
Methods: This study utilized single-cell transcriptome analysis on aortic specimens from three TAK patients, with control data sourced from a publicly available database (GSE155468).
PLoS One
March 2025
Department of Cardiovascular Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Objective: To summarize the existing evidence from double-blind randomized controlled trials (RCTs) and cohort studies regarding the effects of biologic agents for the treatment of large vessel vasculitis (LVV).
Methods: A systematic review and meta-analysis was conducted using MEDLINE, Embase, Cochrane Central Registry of Controlled Trials, and ClinicalTrials.gov covering the period from database inception to May 3rd, 2023.
Arch Rheumatol
December 2024
Department of Internal Medicine, Division of Rheumatology, Marmara University Faculty of Medicine, İstanbul, Türkiye.
Objectives: This study aimed to investigate the expression of proinflammatory cytokines under long-term T helper (Th) 17 cell inducing conditions in Takayasu arteritis (TAK), a granulomatous vasculitis with adaptive immune responses.
Patients And Methods: This cross-sectional study was conducted between May 2014 and April 2017. Peripheral blood mononuclear cells from 25 patients (23 females, 2 males; mean age: 42.
J Hepatol
March 2025
Department of Hepatology, Institute for Liver and Digestive Health, University College London, Royal Free Campus, London, United Kingdom. Electronic address:
Background & Aims: The heterogenous presentation patterns in decompensated cirrhosis confers variable outcomes. While acute decompensation (AD) is well-characterised with poorest prognosis, presentation as non-acute decompensation (NAD) remain unclear. This study aimed to characterize clinical and pathophysiological features of NAD in comparison with healthy (HC), compensated cirrhosis (CC) and AD and identify predictors of progression in NAD.
View Article and Find Full Text PDFRespir Investig
March 2025
Division of Pulmonary Circulation, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, 564-8565, Japan. Electronic address:
Background: The clinical impact of acute vasoreactivity testing with inhaled nitric oxide (NO testing) in severe pulmonary hypertension associated with lung disease (LD-PH) remains unknown.
Methods: We retrospectively reviewed 48 consecutive patients with severe LD-PH (73 ± 9 years; male: 81%) who underwent NO testing between 2014 and 2022. We conducted an exploratory analysis of the association between the response to NO testing and both the efficacy of pulmonary vasodilators and prognosis.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!